Introduction: Andrographolide (ANDR), a key bioactive compound from Andrographis paniculata, has a long history in traditional medicine but is limited by low bioavailability and solubility. This has sparked significant medicinal chemistry efforts to develop more effective derivatives. This review offers a detailed and current synthesis of ANDR derivatives and their improvements in bioavailability, emphasizing their pharmacological actions, structure-activity relationships, chemical modifications, and patent landscape. Method: The review systematically examines evidence from recent literature and patents, emphasizing chemical strategies for modifying the ANDR scaffold, and summarizes biological evaluation results, including cell-based, in vivo, and mechanistic studies of new synthetic and semi-synthetic compounds. Result: A broad range of ANDR derivatives are described, including C-3, C-12, C-14, and C-19 modifications delivering substantial potency gains across multiple therapeutic areas. Recent analogs demonstrated superior efficacy to the parent compound, such as compound 36e (IC50 = 0.59 µM for MCF-7 cells), compound 41d (ALT = 487.6 IU/L, AST = 742.4 IU/L for hepatoprotection), and compound 19i (IC50 = 0.30 µM for anti-platelet aggregation), far surpassing native ANDR (with typical IC50 8.48 µM or higher). Esterification and hybridization have produced analogs with drastically enhanced inhibition rates (e.g., >85% antifibrotic effect, 93.92% tumor reduction, up to 92% inhibition of bacterial biofilm formation), and several derivatives show reduced cytotoxicity, increased bioavailability, and expanded pharmacological scope Discussion: The findings suggest that thoughtful modifications to the ANDR scaffold—especially at the C-3, C-12, C-14, and C-19 positions, as well as the lactone moiety—have the potential to enhance potency, selectivity, and pharmacokinetic properties. However, the majority of derivatives remain in the preclinical phase, and challenges such as inadequate solubility, incomplete toxicity assessments, and limited pharmacokinetic data continue to hinder clinical advancement. Conclusion: This review uniquely integrates detailed structure-activity data, advanced synthesis schemes, and quantifiable pharmacological outcomes from recent studies and patents, distinguishing itself from earlier reviews by presenting the most potent, selective, and safest ANDR-based analogs for translational research. The combined focus on numerical efficacy measures and synthetic innovation provides a roadmap for future drug development targeting major human diseases.
Sharma et al. (Fri,) studied this question.